| Methods |
Crossover design; each phase 2 weeks. All patients assumed to have completed the study. Double blind study (code in sealed envelope). Concurrent asthma medication: 2 groups of patients ‐ 12 had inhaled & oral steroids; 10 had no steroids. |
| Participants |
Inclusion criteria: patients had asthma ‐ diagnosis ATS criteria and >15% reversibiliy. Patient details: 22 participants; age 44‐77; moderate‐severe asthma (2 homogeneous groups); no information on atopy or concurrent COPD. |
| Interventions |
2 interventions: atropine methonitrate 2mg and placebo, nebulised; both interventions q.i.d. (unclear when). |
| Outcomes |
FEV at 2 weeks; daily symptom scores and PEF not reported in results (but 'no difference'). |
| Notes |
Authors stated that the allocation schedule was sealed in envelopes until the study was completed. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
Information not available (Cochrane Grade B) |
